The Relationship between the M1/M2 Macrophage Polarization and the Degree of Ossicular Erosion in Human Acquired Cholesteatoma: An Immunohistochemical Study.
cholesteatoma
inflammation
macrophages
polarization
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
18 Aug 2022
18 Aug 2022
Historique:
received:
19
06
2022
revised:
12
08
2022
accepted:
16
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
The differential involvement of the macrophage activation phenotypes (M1 vs. M2) has been linked to disease severity in various chronic inflammatory disorders. Pharmacologic manipulation of the M1/M2 macrophage polarization has shown therapeutic potential. Cholesteatoma is a destructive chronic middle ear disease with potentially life-threatening complications. The distribution of macrophage polarization phenotypes in middle ear cholesteatoma has not been described. In the present study, human cholesteatoma specimens acquired during tympanomastoidectomy were retrospectively retrieved and immunohistochemically characterized using a combination of antibodies labeling M1 macrophages (CD80), M2 macrophages (CD163), and total macrophages (CD68). The correlations between the immunohistochemical findings and clinical presentation were assessed. The findings revealed that cholesteatomas with more extensive ossicular erosion demonstrated a significantly higher number of M1 (CD80+) cells and a higher M1/M2 ratio than less invasive cholesteatomas (Wilcoxon test, p < 0.05). The extent of ossicular erosion correlated significantly with the M1/M2 ratio (Spearman correlation coefficient ρ = 0.4, p < 0.05). Thus, the degree of ossicular erosion in human acquired cholesteatoma appears to be related to the M1/M2 macrophage polarization. The investigation of macrophage polarization and functions in various clinical presentations of middle ear cholesteatoma is of great interest since it may contribute to the development of pharmaceutical treatment approaches.
Identifiants
pubmed: 36013064
pii: jcm11164826
doi: 10.3390/jcm11164826
pmc: PMC9410162
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Braz J Otorhinolaryngol. 2008 Nov-Dec;74(6):835-841
pubmed: 19582339
Eur Arch Otorhinolaryngol. 2004 Jan;261(1):6-24
pubmed: 12835944
Ann Rheum Dis. 2008 May;67(5):620-4
pubmed: 17720725
Cell Rep. 2019 Apr 23;27(4):1176-1189.e5
pubmed: 31018132
Ann Otol Rhinol Laryngol. 2019 Apr;128(4):365-368
pubmed: 30632386
Clin Exp Otorhinolaryngol. 2016 Dec;9(4):298-308
pubmed: 27440129
Braz J Otorhinolaryngol. 2006 Sep-Oct;72(5):641-8
pubmed: 17221056
Arch Otolaryngol Head Neck Surg. 2002 Oct;128(10):1129-33
pubmed: 12365883
JAMA Otolaryngol Head Neck Surg. 2015 Nov;141(11):974-82
pubmed: 26502037
Am J Otol. 1990 Jul;11(4):247-9
pubmed: 2399942
Infect Immun. 1999 Aug;67(8):3824-9
pubmed: 10417144
Eur Arch Otorhinolaryngol. 2015 Dec;272(12):3601-9
pubmed: 25227761
J Int Adv Otol. 2017 Aug;13(2):272-275
pubmed: 28716767
Cells. 2020 Jan 14;9(1):
pubmed: 31947538
Int J Pediatr Otorhinolaryngol. 2020 Aug;135:110080
pubmed: 32413646
Int J Pediatr Otorhinolaryngol. 2020 Nov;138:110170
pubmed: 32705986
Immunol Invest. 2021 Aug;50(6):609-621
pubmed: 32573304
Cell. 2000 Dec 22;103(7):1071-83
pubmed: 11163183
Acta Otorhinolaryngol Belg. 1993;47(1):33-6
pubmed: 8470548
Braz J Otorhinolaryngol. 2011 Jun;77(3):341-7
pubmed: 21739009
Otolaryngol Clin North Am. 2006 Dec;39(6):1143-59
pubmed: 17097438
Laryngorhinootologie. 2022 Apr;101(4):310-319
pubmed: 34233375
Otol Neurotol. 2003 Sep;24(5):709-13
pubmed: 14501443
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
J Int Adv Otol. 2017 Apr;13(1):1-8
pubmed: 28059056
Am J Otol. 1998 Jan;19(1):7-19
pubmed: 9455941
Eur Arch Otorhinolaryngol. 2017 May;274(5):2071-2078
pubmed: 27981350
Front Microbiol. 2021 Nov 05;12:761111
pubmed: 34803987
Front Cell Dev Biol. 2021 Mar 02;9:625423
pubmed: 33738283
Int J Pediatr Otorhinolaryngol. 2012 Mar;76(3):319-21
pubmed: 22264818
Biomed Res Int. 2015;2015:854024
pubmed: 25866816
Immunity. 2010 May 28;32(5):593-604
pubmed: 20510870
J Assoc Res Otolaryngol. 2019 Oct;20(5):449-459
pubmed: 31254133
Eur Arch Otorhinolaryngol. 2021 Mar;278(3):665-673
pubmed: 32535859
Acta Otorhinolaryngol Ital. 2009 Aug;29(4):197-202
pubmed: 20161877
Cell Commun Signal. 2021 Feb 24;19(1):25
pubmed: 33627146
Braz J Otorhinolaryngol. 2007 Jan-Feb;73(1):117-21
pubmed: 17505610
Cell Biochem Biophys. 2011 Jun;60(1-2):77-88
pubmed: 21455682
Otol Neurotol. 2008 Oct;29(7):933-40
pubmed: 18667943
Clin Exp Immunol. 2014 Sep;177(3):703-11
pubmed: 24816497
Sci Rep. 2015 Dec 07;5:16683
pubmed: 26639190
J Immunol Res. 2018 Jan 14;2018:8917804
pubmed: 29507865
Front Immunol. 2015 Jul 22;6:370
pubmed: 26257737
Am J Otol. 2000 Nov;21(6):786-92
pubmed: 11078064
Front Immunol. 2019 Aug 20;10:1875
pubmed: 31481956
Exp Mol Pathol. 2010 Apr;88(2):316-23
pubmed: 20045407
BMC Cancer. 2015 Aug 05;15:573
pubmed: 26242181
Am J Otolaryngol. 1991 Sep-Oct;12(5):249-53
pubmed: 1811419
Ann Otol Rhinol Laryngol. 1972 Feb;81(1):1-11
pubmed: 5009814
HNO. 1998 May;46(5):494-501
pubmed: 9647920
Laryngoscope. 2008 Jan;118(1):94-8
pubmed: 17989584
Inflamm Res. 2016 Jan;65(1):1-11
pubmed: 26467935
PLoS One. 2012;7(12):e52718
pubmed: 23285167
Int Arch Otorhinolaryngol. 2020 Jan;24(1):e18-e23
pubmed: 31915464
Arch Otolaryngol Head Neck Surg. 2006 Sep;132(9):931-3
pubmed: 16982968
Otol Neurotol. 2012 Apr;33(3):387-92
pubmed: 22410730
Front Immunol. 2019 Jan 18;10:3
pubmed: 30713533
Arch Immunol Ther Exp (Warsz). 2016 Jun;64(3):241-7
pubmed: 26584851
Ear Nose Throat J. 2021 Jun;100(3_suppl):249S-252S
pubmed: 31581829
Am J Otolaryngol. 2008 Jan-Feb;29(1):1-6
pubmed: 18061824
Eur Arch Otorhinolaryngol. 1992;249(2):87-90
pubmed: 1581051
Otol Neurotol. 2016 Mar;37(3):214-7
pubmed: 26808554
Otol Neurotol. 2019 Jan;40(1):63-72
pubmed: 30339650
Am J Otol. 1999 Mar;20(2):158-61
pubmed: 10100515
OTO Open. 2021 Nov 23;5(4):2473974X211059111
pubmed: 34870062